In a recent clinical trial (NCT05566223) using CISH as the intracellular checkpoint target, researchers propose to knock out CISH by CRISPR system in TILs from patients with metastatic NSCLC in order to evaluate the safety and efficacy of genetically engineered TIL therapy. The gene discussed is CISH; the disease is non-small cell lung carcinoma.